{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid+Formula&page=2", "query": { "intervention": "Amino Acid Formula", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid+Formula&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T21:27:40.110Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04460326", "title": "Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Treated With Insulin" ], "interventions": [ { "name": "Insulin glargine", "type": "DRUG" }, { "name": "NovoLog", "type": "DRUG" }, { "name": "Insulin Fiasp", "type": "DRUG" }, { "name": "Standard carbohydrate diet", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 137, "start_date": "2020-12-07", "completion_date": "2023-05-27", "has_results": true, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460326" }, { "nct_id": "NCT01295944", "title": "Carboplatin and Bevacizumab for Recurrent Ependymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ependymoma", "Anaplastic Ependymoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2011-04-27", "completion_date": "2021-05-14", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01295944" }, { "nct_id": "NCT04163432", "title": "Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2020-06-18", "completion_date": "2026-02-23", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04163432" }, { "nct_id": "NCT05234593", "title": "Feasibility and Acceptability of Powdered Multinutrient Formula", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "EmpowerPlus Lightning Sticks", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "7 Years to 16 Years" }, "enrollment_count": 20, "start_date": "2022-08-01", "completion_date": "2023-04-30", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05234593" }, { "nct_id": "NCT00598169", "title": "Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 23, "start_date": "2007-11", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598169" }, { "nct_id": "NCT02066610", "title": "Effect of Selenium Supplementation on Trace Mineral Antioxidant Enzyme and Amino Acid Metabolism in Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Preterm Infants" ], "interventions": [ { "name": "selenium and sodium selenate supplementation", "type": "OTHER" }, { "name": "selenium and sodium selenite supplementation", "type": "OTHER" }, { "name": "Without selenium and sodium selenate supplementation", "type": "OTHER" }, { "name": "Without selenium and sodium selenite supplementation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abbott Nutrition", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "1991-03", "completion_date": "1993-06", "has_results": false, "last_update_posted_date": "2014-02-19", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02066610" }, { "nct_id": "NCT03394885", "title": "Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2018-06-19", "completion_date": "2020-07-20", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Durham, North Carolina • Charlottesville, Virginia", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394885" }, { "nct_id": "NCT05262556", "title": "NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Neoplasm", "Neuroendocrine Carcinoma", "Mixed Neuroendocrine-Non Neuroendocrine Neoplasm" ], "interventions": [ { "name": "NP-101 (TQ Formula)", "type": "DRUG" }, { "name": "Nivolumab (3mg/kg)", "type": "DRUG" }, { "name": "Ipilimumab (1mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amr Mohamed MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2022-12-15", "completion_date": "2025-10-27", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262556" }, { "nct_id": "NCT00396097", "title": "Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Short Stature" ], "interventions": [ { "name": "Genotropin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "10 Years", "sex": "ALL", "summary": "3 Years to 10 Years" }, "enrollment_count": 316, "start_date": "2006-12", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2016-04-05", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 43, "location_summary": "Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more", "locations": [ { "city": "Little Rock", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00396097" }, { "nct_id": "NCT00023244", "title": "Steroid Withdrawal in Pediatric Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Bactrim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Day to 20 Years" }, "enrollment_count": 274, "start_date": "2001-01", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-09-28T21:27:40.110Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023244" } ] }